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longer disease duration (0.96; 0.94, 0.98) and worse HAQ (0.74; 0.60, 0.92). Social 
functioning improved with better VASQOL (8.62; 3.32, 13.91), but worsened with 
more comorbidities (−0.92; −1.49, −0.35), anxiolytic and/or antidepressant use (−5.33; 
−7.68, −2.98), worse RADAI (−1.54; −2.80, −0.28), HAQ (−8.38; −10.51, −6.25) and 
fatigue (−1.06; −1.48, −0.65). Furthermore, the mechanism by which RADAI affected 
social functioning did not appear to be through pain (0.20; −0.43, 0.84), but through 
HAQ as it absorbed 56% of the explanatory power of RADAI. CONCLUSIONS: 
Performance of social roles was limited among RA patients with more HAQ disability, 
and improved by better quality of life. Disease activity appeared to inﬂ uence social 
functioning through worse physical disability but not through pain.
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BACKGROUND: Disease activity and disability should be assesssed at each rheuma-
toid arthritis (RA) patient visit to monitor response to therapy. Disease activity has 
been traditionally evaluated by the disease activity scale (DAS-28) and the ACR cri-
teria, which depend on physicians, but few studies have analyzed short-term predictors 
of the patient self-reported RA disease activity index-RADAI. Disability is routinely 
assessed by the health assessment questionnaire (HAQ) whose long term predictors, 
but not short-term, have been extensively studied. OBJECTIVES: To analyze whether 
the 6-month baseline levels of HAQ and of RADAI and other factors predict change 
at 6-month intervals. METHODS: RA patients from the biannual NDB-Portugal 
cohort were used. For each patient, differences between two consecutive 6-month 
intervals were computed for HAQ (0–3, 3 is worse) and RADAI (0–10, 10 is worse). 
For each scale, a binary outcome was constructed based upon these differences, where 
a positive increment meant worsening in function and disease activity. Patients’ obser-
vations whose increments were null were excluded. Univariate (UV) and multivariate 
(MV) generalized estimating equations were used. Factors included age, sex, marital 
status, disease duration, education level, number of major comorbidities, paid work 
status and 6-month baseline HAQ and RADAI levels. RESULTS: MV analyses 
revealed that the main predictors of HAQ were baseline HAQ: (OR: 0.49, 95% CI 
0.44, 0.54), number of comorbidities (1.09 (1.05, 1.14)), and age (1.02 (1.01, 1.02)); 
For RADAI they were, baseline RADAI (0.69 (0.66, 0.73)), comborbidities (1.11 
(1.07, 1.16)), and educational level (0.95 (0.93, 0.97)). CONCLUSIONS: Worse 
baseline levels of HAQ and RADAI predicted their respective improvement 6-months 
later. This could be due to optimization of treatment strategies when worse baseline 
scores are detected, but whatever the reason, performing these two patient reported 
outcomes are a quick and non-rheumatologist dependent way to improve patients’ 
disease status over 6-month intervals.
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OBJECTIVES: The demand for comparative effectiveness research (CER) data from 
payers, physicians, and patients is signiﬁ cant, but the cost and time associated with 
prospective randomized trials is a barrier to rapid decision-making. Use of patient-
reported outcomes (PROs) collected via on-line patient communities provides one 
channel for rapid data collection, particularly in conditions such as rheumatoid arthri-
tis (RA), where validated PRO instruments are available. METHODS: A random 
sample of iGuard.org members in the US treated with non-steroidal anti-inﬂ ammatory 
drug (NSAIDs), oral disease-modifying antirheumatic drugs (DMARDs), or biologics 
for RA completed the Rheumatoid Arthritis Disease Activity Index (RADAI) and a series 
of other questions related to their disease. iGuard.org is a free medication monitoring 
service that is introduced to patients through multiple sources including physician, 
pharmacy and online referrals. For this study, we report pilot baseline data on patient-
reported RADAI, pain, and joint counts across the three treatment groups to demon-
strate use of on-line communities in supporting CER. RESULTS: A total of 153 RA 
patients completed the study: 49 treated with NSAIDs only, 51 exposed to oral 
DMARDs, and 53 exposed to biologics. The mean (SD) RADAI score was 4.59 (2.16). 
Adjusting for age and gender and multiple comparisons, there were signiﬁ cant differ-
ences between the three treatment groups on RADAI scores (p = 0.0045) and patient 
global assessment of pain (p = 0.0357) but not on the number of painful joints (p = 
0.3512). The trend was towards patients on NSAIDs only having worse outcomes 
compared to patients on biologics or patients on oral DMARDs. CONCLUSIONS: 
This pilot study demonstrates the possibility of collecting baseline disease severity data 
directly from patients using the RADAI, which is sensitive to detect differences by 
treatment modality. The next step in the pilot program will be to investigate the 
potential for capturing longitudinal disease progress information amongst patients in 
on-line communities. 
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OBJECTIVES: To examine the pattern of palivizumab utilization and compliance in 
infants with pre-existing disease within the Canadian Registry Database (CARESS). 
METHODS: A prospective, registry of infants across 27 sites who received at least 1 
dose of palivizumab during the 2006–2009 RSV seasons. Neonatal and demographic 
data were collected from the parent/caregiver at enrollment. Data on palivizumab 
utilization, compliance, and outcomes related to respiratory illness (RI) events were 
collected monthly. Premature infants ≤35 completed weeks gestational age without 
medical conditions who met standard approval criteria for palivizumab (Group 1) 
were compared to those with underlying medical disorders who received prophylaxis 
(Group 2). RESULTS: Group 1 (n = 3379) Group 2 (n = 489). Male: 56.8% versus 
54.6% (P = 0.433). Average Enrollment Age (months) ± SD: 3.6 ± 3.4 versus 9.9 ± 
8.8 (P = 0.000). Average GA (weeks) Mean ± SD: 31.0 ± 3.1 versus 37.1 ± 4.3 (P = 
0.000). Average # injections ± SD: 3.6 ± 1.5 versus 3.7 ± 1.5 (P = 0.159). Hospitaliza-
tion Rate (HR) for RI: 4.1% versus 9.2% (P = 0.000). RSV HR: 1.3% versus 2.7% 
(P < 0.05). On average infants received 86.0% ± 28.3% of the expected number of 
injections. Group 2 infants comprised Down syndrome (n = 118, 24.1%), upper 
airway anomalies (n = 112, 22.9%), cystic ﬁ brosis (n = 62, 12.7%), neuromuscular 
impairment (n = 42, 8.6%), pulmonary (n = 38, 7.8%), multiple system disorders (n 
= 34, 7.0%), cardiac (n = 17, 3.5%), immunocompromise (n = 8, 1.6%), and miscel-
laneous (n = 58, 11.9%). From 2006–2009, the proportion of Group 2 infants receiv-
ing prophylaxis increased 2-fold from 5.6% (69/1224) to12.2% (245/2016). Overall. 
Group 2 infants were older at enrollment with more advanced GA and had signiﬁ -
cantly higher RI and RSV hospitalization rates. No serious adverse events directly 
related to palivizumab occurred. CONCLUSIONS: Results imply that infants with 
underlying medical disorders that are not approved for prophylaxis by advisory bodies 
and current position statements are at greater risk for RSV infections and 
hospitalization.
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OBJECTIVES: Palivizumab is used for respiratory syncytial virus (RSV) prophylaxis 
in high risk children. Data on seasonality, risk factors, and outcomes are necessary to 
evaluate the impact of palivizumab on the incidence of RSV infections, minimize health 
care resources and identify which infant sub-sets are receiving prophylaxis.To deter-
mine current usage of palivizumab prophylaxis, compliance patterns, hospitalization 
rate (HR) and outcomes in children at high-risk of respiratory syncytial virus (RSV) 
infection through a Canadian Registry Database (CARESS). METHODS: A prospec-
tive, study of infants who received at least 1 dose of palivizumab in the 2006–2009 
RSV seasons across 27 sites. Neonatal and demographic data were collected upon 
enrolment. Parents/caregivers were contacted monthly for data on palivizumab utiliza-
tion, compliance and outcomes related to any respiratory tract events. RESULTS: A 
total of 4926 infants aged 2 days–47 months (mean = 5.4 months) were enrolled. 
Participants were typically male (57.1%) and Caucasian (70.8%). Gestational age 
(GA) was 32.2 ± 4.6 completed weeks. 3480 (70.6%) premature infants received 
palivizumab (≤35 completed weeks GA), 403 (8.2%) required O2, 471 (9.6%) had 
congenital heart disease and 572 (11.6%) were prophylaxed for other risk factors. On 
average patients received 3.7 ± 1.5 injections, with 17,982 doses given overall. There 
were no drug related serious adverse events.296 infants required 357 hospitalizations 
for respiratory tract infections with a hospitalization rate of 6.0%. There were signiﬁ -
cant differences between indications for palivizumab (chi-square = 71.8, P < 0.005).
The overall RSV positive HR was 1.38%. Hospitalization rates were highest in infants 
of aboriginal descent (15.0%, chi-square = 22.2, P < 0.005). Hospitalized infants had 
a lower percentage of compliant injections (62.8% versus 68.6%, p = 0.003). CON-
CLUSIONS: The RSV HR in the 2006–2009 RSV seasons resembled several published 
reports (range 1.3%–5.3%). RSV HR may be decreasing because of compliance with 
palivizumab prophylaxis, variability in RSV epidemiology, hospital admission criteria 
and preventive education.
PRS3
COMORBIDITY PROFILING OF COPD PATIENTS IN THE UNITED 
KINGDOM PRIMARY CARE USING AN INCIDENCE BASED APPROACH 
TO DETECT ASSOCIATIONS WITH THE DISEASE
Kiri VA
PAREXEL International, Uxbridge, London, UK
OBJECTIVES: Comorbidity is an important factor in any comparative assessment of 
treatments associated with morbidity and mortality of patients. Many factor such as 
age, gender and duration of a disease can inﬂ uence the impact of comorbid diseases 
on quality of life. In the health care setting (the primary source of data for most 
observational studies), the decision to give a particular treatment to a particular 
patient with a given disease is generally based on patient speciﬁ c characteristics, the 
most important of which is disease condition. Thus, confounding by indication/disease 
